Hydroxyurea
Treatment for Sickle Cell Disorders
Typical Dosage: 15-35 mg/kg/day, titrated
Effectiveness
85%
Safety Score
60%
Clinical Trials
150
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
15-35 mg/kg/day, titrated
Time to Effect
3-6 months
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300
Monitoring:$750
Side Effect Mgmt:$350
Total Annual:$1,400
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$2,000
Hydroxyurea Outcomes
for Sickle Cell Disorders
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+70%
Common Side Effects
Myelosuppression (neutropenia, anemia, thrombocytopenia)
+25%
Gastrointestinal upset (nausea, vomiting, diarrhea)
+15%
Skin hyperpigmentation
+12%
Leg ulcers
+3%
Sources:
Active Clinical Trials
6 active trials recruiting for Hydroxyurea in Sickle Cell Disorders
Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease
NCT06578507RECRUITINGPHASE2
50 participants
INTERVENTIONAL
Créteil, France +5 more
Started: Jan 21, 2025
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study
NCT04707235ACTIVE NOT RECRUITING
2.09K participants
OBSERVATIONAL
Amiens, France +86 more
Started: Aug 21, 2020
Therapeutic Response Evaluation and Adherence Trial (TREAT)
NCT02286154ACTIVE NOT RECRUITINGNA
150 participants
INTERVENTIONAL
Cincinnati, United States
Started: Oct 1, 2014
Realizing Effectiveness Across Continents With Hydroxyurea (REACH)
NCT01966731ACTIVE NOT RECRUITINGPHASE1, PHASE2
635 participants
INTERVENTIONAL
Luanda, Angola +3 more
Started: Jun 1, 2014
Realizing Effectiveness Across Continents With Hydroxyurea
NCT06171217ACTIVE NOT RECRUITINGPHASE2
810 participants
INTERVENTIONAL
Luanda, Angola +3 more
Started: Oct 27, 2023
Alternative Dosing And Prevention of Transfusions (ADAPT)
NCT05662098ACTIVE NOT RECRUITINGEARLY_PHASE1
100 participants
INTERVENTIONAL
Jinja, Uganda
Started: Jun 16, 2022
Completed Clinical Trials
11 completed trials for Hydroxyurea in Sickle Cell Disorders
Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in Kinshasa
NCT05681598COMPLETEDNA
166 participants
INTERVENTIONAL
Kinshasa, Democratic Republic of the Congo
Started: Aug 30, 2017
Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.
NCT05470270COMPLETEDPHASE2
33 participants
INTERVENTIONAL
Créteil, France +2 more
Started: Jul 8, 2022
Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment
NCT02149537COMPLETEDPHASE4
53 participants
INTERVENTIONAL
Ibadan, Nigeria
Started: Dec 1, 2014
Mobile-Directly Observed Therapy on Adherence to Hydroxyurea
NCT02844673COMPLETEDPHASE2
98 participants
INTERVENTIONAL
Dar es Salaam, Tanzania
Started: Apr 28, 2017
Sickle Cell Disease - Stroke Prevention in Nigeria Trial
NCT01801423COMPLETEDNA
29 participants
INTERVENTIONAL
Kano, Nigeria
Started: Apr 24, 2013
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
NCT01506544COMPLETEDPHASE1
39 participants
INTERVENTIONAL
Birmingham, United States +5 more
Started: Dec 1, 2011
Hydroxyurea and Transfusion
NCT03644953COMPLETEDPHASE2
14 participants
INTERVENTIONAL
Washington D.C., United States
Started: Oct 30, 2018
Hydroxyurea Optimization Through Precision Study
NCT03789591COMPLETEDPHASE3
104 participants
INTERVENTIONAL
Phoenix, United States +12 more
Started: Jan 17, 2019
Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
NCT00890396COMPLETED
163 participants
OBSERVATIONAL
Birmingham, United States +13 more
Started: Sep 1, 2008
Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
NCT02225132COMPLETEDPHASE1, PHASE2
10 participants
INTERVENTIONAL
Bethesda, United States
Started: Aug 23, 2014
Hydroxyurea in Young Children With Sickle Cell Anemia
NCT00519701COMPLETEDNA
14 participants
INTERVENTIONAL
Durham, United States
Started: Apr 1, 2002
Showing 20 of 150 total trials